Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021067421 - PREPARING THERAPEUTICALLY ENHANCED HUMAN MESENCHYMAL STEM CELLS AND USES THEREOF

Publication Number WO/2021/067421
Publication Date 08.04.2021
International Application No. PCT/US2020/053521
International Filing Date 30.09.2020
IPC
A61K 35/12 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K 35/28 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 35/32 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
A61P 19/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
C12N 5/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N 5/02 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
02Propagation of single cells or cells in suspension; Maintenance thereof; Culture media therefor
Applicants
  • UNIVERSITY OF MIAMI [US]/[US]
Inventors
  • CORREA, Diego
  • KOUROUPIS, Dimitrios
  • BOWLES, Annie, C.
  • KAPLAN, Lee, D.
  • BEST, Thomas, M.
Agents
  • FENDRICK, Sarah, E.
Priority Data
62/908,92301.10.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PREPARING THERAPEUTICALLY ENHANCED HUMAN MESENCHYMAL STEM CELLS AND USES THEREOF
(FR) PRÉPARATION DE CELLULES SOUCHES MÉSENCHYMATEUSES HUMAINES THÉRAPEUTIQUEMENT AMÉLIORÉES ET LEURS UTILISATIONS
Abstract
(EN)
The present disclosure generally relates to methods for preparing human mesenchymal stem cells (hMSCs) that express high CD10 phenotypes. The present disclosure further relates to methods of treating local inflammation, fibrosis, and/or musculoskeletal pain using hMSCs that express high CD10 phenotypes. This invention provides methods for producing clinically relevant amounts of MSCs that do not involve FBS or other animal-derived media, supplements, or components, wherein the MSCs produced thereby can be more safely used for treating appropriate diseases and disorders in humans and other animals.
(FR)
La présente divulgation concerne d'une manière générale des procédés de préparation de cellules souches mésenchymateuses humaines (hMSC) qui expriment des phénotypes CD10 élevé. La présente divulgation concerne en outre des méthodes de traitement d'une inflammation locale, d'une fibrose et/ou d'une douleur musculosquelettique faisant appel aux hMSC qui expriment des phénotypes CD10 élevé. Cette invention concerne des procédés de production de quantités de de MSC pertinentes sur le plan clinique, qui ne font pas appel au FBS ou à d'autres milieux, suppléments ou composants d'origine animale, les MSC ainsi produites pouvant être utilisées de façon plus sûre pour traiter des maladies et troubles appropriés chez les êtres humains et d'autres animaux.
Latest bibliographic data on file with the International Bureau